Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs QURE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

QURE Captures Overall Composite Edge (48.9 HOLD vs 45.3 HOLD), While RGNX Leads 3–2 on Growth & Valuation Pillars

QURE Overall Winner 6-Pillar Tally: RGNX 3 – 2 QURE (1 Tie) Matrix Metrics: RGNX 2 – 8 QURE

As of Nov 16, 2026, uniQure N.V. (QURE) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (48.9/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while RGNX wins 3–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus QURE at $22.02 (27.9x Forward P/E, -994.0% operating margin).

  • Growth vs. Quality Trade-Off: QURE earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. RGNX 45.3/100 HOLD) and 0.80β · 81% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile QURE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs QURE
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
QURE NASDAQ Head-to-Head Winner
uniQure N.V.
Pharmaceutical Preparations
$22.02
-7.52% 1D
Market Cap $1.7B
TTM Revenue $20M
Forward P/E 27.9x
Beta / 30D Vol 0.80β · 81% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 42.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.1%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $23.25 · SMA50: $29.05

6-Pillar Scorecard Institutional Category Breakdown (RGNX 3 – 2 QURE)

Columns: Metric · RGNX · QURE
1. Valuation Multiples QURE
Forward P/E N/M 27.9x
Trailing P/E N/M 27.9x
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 83.9x
2. Growth & Scale QURE
Revenue Growth (YoY) -69.2% +40.4%
Earnings Growth (YoY) +0.0% -18.2%
TTM Revenue (USD) $154M $20M
Market Cap $500.9M $1.7B
3. Profitability & Quality RGNX
Gross Margin -64.5% N/A
Operating Margin -120.4% -994.0%
Net Profit Margin -113.9% 0.0%
Return on Equity (ROE) -113.2% -89.0%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$193M
Cash Flow Margin -100.6% N/A
Net Cash / Leverage $29M Net Cash $36M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 349.6% (52nd %ile) 56.2% (<1st %ile)
Put/Call OI Skew N/A 0.14x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (2) vs QURE (8)
Institutional Metric RGNX QURE Criterion Row Edge
Market Capitalization
Scale
$500.9M $1.7B Larger Scale QURE
Trailing P/E Ratio
Valuation
N/M 27.9x Lower Multiple QURE
Forward P/E Ratio
Valuation
N/M 27.9x Lower Multiple QURE
Revenue Growth (YoY)
Growth
-69.2% +40.4% Higher Growth QURE
Operating Margin (TTM)
Profitability
-120.4% -994.0% Higher Margin RGNX
Net Profit Margin
Profitability
-113.9% 0.0% Higher Margin QURE
Return on Equity (ROE)
Capital Efficiency
-113.2% -89.0% Higher ROE QURE
52-Week Range Position
Momentum
19% ($5–$16) 31% ($9–$52) Stronger Trend QURE
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 0.80β · 81% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite QURE
Trailing 12M Revenue (USD)
Operating Scale
$154M $20M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 83.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$193M ($36M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RGNX +6.77 pp
RGNX: +7.87% · QURE: +1.1%
3M Horizon RGNX +21.0 pp
RGNX: -32.52% · QURE: -53.52%
6M Horizon RGNX +43.88 pp
RGNX: +32.21% · QURE: -11.67%
1Y Horizon QURE +8.4 pp
RGNX: -35.82% · QURE: -27.42%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue QURE Revenue RGNX Op. Margin QURE Op. Margin Margin Leader
FY2018 $220M $10M 40.3% -781.9% RGNX
FY2019 $40M $10M -422.9% -1663.8% RGNX
FY2020 $150M $40M -77.1% -334.3% RGNX
FY2021 $470M $520M 34.0% 59.3% QURE
FY2022 $110M $110M -233.2% -134.4% QURE
FY2023 $90M $20M -297.1% -1785.5% RGNX
FY2024 $80M $30M -280.0% -679.6% RGNX
FY2025 $170M $20M -94.6% -1151.4% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
QURE BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 56.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact QURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
QURE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -994.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs QURE Key Questions & Quantitative Answers

As of Nov 16, 2026, uniQure N.V. (QURE) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (48.9/100 HOLD vs. 45.3/100 HOLD) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while RGNX wins 3–2 across the 6-pillar growth and valuation breakdown. RGNX trades at $7.47 (N/M Forward P/E, -120.4% operating margin) versus QURE at $22.02 (27.9x Forward P/E, -994.0% operating margin). Growth vs. Quality Trade-Off: QURE earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. RGNX 45.3/100 HOLD) and 0.80β · 81% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile QURE is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

QURE leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with QURE at +40.4% YoY revenue growth and -18.2% YoY earnings growth on $20M TTM revenue (N/A gross margin, -994.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while QURE shifted +100.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for QURE.

QURE screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas QURE trades at 27.9x Forward P/E, 27.9x Trailing P/E, N/M PEG, and 83.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus QURE (-89.0% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, QURE carries 56.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.80β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.